The results of this research have enabled drugs to be developed that represent real benefit for patients. Thus biopharmaceuticals (‘biologics’) have been designed to treat rheumatoid arthritis by selectively intervening in the molecular mechanism of disease development – without weakening the immune system as a whole. Such treatments relieve pain and keep the disease at bay.
The earlier rheumatoid arthritis is diagnosed, the better joint damage and its associated threat of disability can be prevented. Roche has developed a reliable diagnostic test for early detection.
A diagnostic test for the early detection of rheumatoid arthritis and identification of the right treatment
The anti-CCP test diagnoses rheumatoid arthritis early in its course, thus enabling progression of this chronic inflammatory autoimmune disease to be stopped as soon as possible.
In patients who fail to respond either to disease-modifying drugs or to treatment with TNF - alpha inhibitors, the anti-CCP test also points physicians to the right treatment: a positive test is an indication for treatment with MabThera, a Roche drug that eliminates the white blood cells responsible for the exaggerated immune system activity seen in autoimmune disease.
The anti-CCP test determines whether the patient’s blood contains antibodies against the citrullinated proteins that play an important role in the pathogenesis of rheumatoid arthritis. These are proteins in which the amino acid arginine has been converted to citrulline.
Using the highly specific Elecsys Anti-CCP diagnostic test we can reliably match the right treatment to the right patient.
Michael Rottmann, Roche Penzberg, Germany